Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Abstract 3696: Evolutionary immunotherapy in NSCLC: identifying optimal dosing strategies in TIL therapy using agent-based modeling

Sandhya Prabhakaran, Mark Robertson-Tessi, Kimberly Luddy, Rafael R. Bravo, Taylor M. Bursell, Julian Pineiro, Jeffrey West, Megan Johnson, Jhanelle A. Gray, Amer A. Beg, Scott J. Antonia, Robert A. Gatenby, Alexander R. Anderson

Cancer Res (2025) 85 (8_Supplement_1): 3696.

https://doi.org/10.1158/1538-7445.AM2025-3696

Published: 21 April 2025

View articletitled, Abstract 3696: Evolutionary immunotherapy in NSCLC: identifying optimal dosing strategies in TIL therapy using agent-based modeling

Journal Articles

Abstract 5571: Collagen stabilization directs immune suppression in the head and neck squamous cell carcinoma hypoxic subtype

Sonal Srivastava, John Powers, Ritu Chaudhary, Sadegh Marzban, Robbert J. Slebos, Jeffrey West, Xiaofei Song, Jose A. Guevara-Patino, Christine H. Chung, Antonio L. Amelio

Cancer Res (2024) 84 (6_Supplement): 5571.

https://doi.org/10.1158/1538-7445.AM2024-5571

Published: 22 March 2024

View articletitled, Abstract 5571: Collagen stabilization directs immune suppression in the head and neck squamous cell carcinoma hypoxic subtype

Journal Articles

Abstract A021: Evolutionary immunotherapy in NSCLC: An integrated approach

Sandhya Prabhakaran, Taylor M. Bursell, Kimberly Luddy, Julian Pineiro, Rafael Bravo, Jeffrey West, Megan Johnson, Mark Robertson-Tessi, Amer A. Beg, Jhanelle E. Gray, Scott Antonia, Robert A. Gatenby, Alexander R. A. Anderson

Cancer Res (2024) 84 (3_Supplement_2): A021.

https://doi.org/10.1158/1538-7445.CANEVOL23-A021

Published: 01 February 2024

View articletitled, Abstract A021: Evolutionary immunotherapy in NSCLC: An integrated approach

Journal Articles

Abstract PR006: Evolution of evolvability

Jill A. Gallaher, Maximilian Strobl, Jeffrey West, Mark Roberston-Tessi, Alexander R. A. Anderson

Cancer Res (2024) 84 (3_Supplement_2): PR006.

https://doi.org/10.1158/1538-7445.CANEVOL23-PR006

Published: 01 February 2024

View articletitled, Abstract PR006: Evolution of evolvability

Journal Articles

Abstract PR008: Cell state transitions drive the evolution of disease progression in B-cell acute lymphoblastic leukemia

Curtis Gravenmier, Ling Zhang, Lynn Moscinski, Jeffrey West

Cancer Res (2024) 84 (3_Supplement_2): PR008.

https://doi.org/10.1158/1538-7445.CANEVOL23-PR008

Published: 01 February 2024

View articletitled, Abstract PR008: Cell state transitions drive the evolution of disease progression in B-cell acute lymphoblastic leukemia

Journal Articles

Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics

Jill Gallaher, Maximilian Strobl, Jeffrey West, Robert Gatenby, Jingsong Zhang, Mark Robertson-Tessi, Alexander R.A. Anderson

Cancer Res (2023) 83 (16): 2775–2789.

https://doi.org/10.1158/0008-5472.CAN-22-2558

Published: 15 August 2023

View articletitled, Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics

Includes: Multimedia, Supplementary data

Journal Articles

Abstract 847: Applying the principles of convexity and concavity to guide treatment scheduling of ALK inhibitors in non-small cell lung cancer

Jeffrey West, Bina Desai, Maximilian Strobl, Luke Pierik, Robert Vander Velde, Mark Robertson-Tessi, Andriy Marusyk, Alexander R. Anderson

Cancer Res (2023) 83 (7_Supplement): 847.

https://doi.org/10.1158/1538-7445.AM2023-847

Published: 04 April 2023

View articletitled, Abstract 847: Applying the principles of convexity and concavity to guide treatment scheduling of ALK inhibitors in non-small cell lung cancer

Journal Articles

Abstract 3164: Disulfiram re-sensitizes ER+ breast cancer cells resistant to chemotherapy through an evolutionary double-bind

Rena Emond, Jeffrey West, Alexander Anderson, Andrea H. Bild

Cancer Res (2023) 83 (7_Supplement): 3164.

https://doi.org/10.1158/1538-7445.AM2023-3164

Published: 04 April 2023

View articletitled, Abstract 3164: Disulfiram re-sensitizes ER+ breast cancer cells resistant to chemotherapy through an evolutionary double-bind

Journal Articles

Abstract 852: Predicting progression in metastatic castrate-sensitive prostate cancer by coupling PSA and testosterone dynamics to a mechanistic mathematical model

Jill Gallaher, Maximilian Strobl, Jeffrey West, Mark Robertson-Tessi, Robert Gatenby, Jingsong Zhang, Alexander R. A. Anderson

Cancer Res (2023) 83 (7_Supplement): 852.

https://doi.org/10.1158/1538-7445.AM2023-852

Published: 04 April 2023

View articletitled, Abstract 852: Predicting progression in metastatic castrate-sensitive prostate cancer by coupling PSA and testosterone dynamics to a mechanistic mathematical model

Journal Articles

Abstract 124: Autocrine signaling extends PD-L1 expression in NSCLC following an active immune response

Taylor M. Bursell, Sandhya Prabhakaran, Kimberly Luddy, Julian Pineriro, Rafael Bravo, Jeffrey West, Mark Robertson-Tessi, Aner Beg, Jhanelle Gray, Scott Antonia, Robert Gatenby, Alexander Anderson

Cancer Res (2023) 83 (7_Supplement): 124.

https://doi.org/10.1158/1538-7445.AM2023-124

Published: 04 April 2023

View articletitled, Abstract 124: Autocrine signaling extends PD-L1 expression in NSCLC following an active immune response

Journal Articles

Abstract PR008: Immunosuppressive niche engineering at the onset of human colorectal cancer

Chandler D. Gatenbee, Ann-Marie Baker, Ryan O. Schenck, Maximilian Strobl, Jeffrey West, Mark Robertson-Tessi, Trevor A. Graham, Alexander R.A. Anderson

Cancer Res (2022) 82 (10_Supplement): PR008.

https://doi.org/10.1158/1538-7445.EVODYN22-PR008

Published: 15 May 2022

View articletitled, Abstract PR008: Immunosuppressive niche engineering at the onset of human colorectal cancer

Journal Articles

Abstract B025: Antifragile therapy

Jeffrey West, Bina Desai, Maximilian Strobl, Luke Pierik, Richard Miles, Cole Armagost, Mark Robertson-Tessi, Andriy Marusyk, Alexander R. A. Anderson

Cancer Res (2022) 82 (10_Supplement): B025.

https://doi.org/10.1158/1538-7445.EVODYN22-B025

Published: 15 May 2022

View articletitled, Abstract B025: Antifragile therapy

Journal Articles

Abstract B006: Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support

Mark Robertson-Tessi, Joel Brown, Maria Poole, Kimberly Luddy, Andriy Marusyk, Jill Gallaher, Jeffrey West, Matthew Johnson, Heiko Enderling, Rikesh Makanji, Joaquim Farinhas, Robert Gatenby, Damon Reed, Christine Chung, Alexander Anderson

Cancer Res (2022) 82 (10_Supplement): B006.

https://doi.org/10.1158/1538-7445.EVODYN22-B006

Published: 15 May 2022

View articletitled, Abstract B006: Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support

Journal Articles

Abstract B033: Immunosuppressive niche engineering at the onset of human colorectal cancer

Chandler D. Gatenbee, Ann-Marie Baker, Ryan O. Schenck, Maximilian Strobl, Jeffrey West, Mark Robertson-Tessi, Trevor A. Graham, Alexander R.A. Anderson

Cancer Res (2022) 82 (10_Supplement): B033.

https://doi.org/10.1158/1538-7445.EVODYN22-B033

Published: 15 May 2022

View articletitled, Abstract B033: Immunosuppressive niche engineering at the onset of human colorectal cancer

Journal Articles

Abstract B023: An integrated approach to understanding the evolutionary dynamics of childhood acute lymphoblastic leukemia from diagnosis to relapse

Virginia A. Turati, Javier Herrero Sanchez, Jeffrey West, Mark Robertson-Tessi, Tariq Enver, Andriy Marusyk, Alexander R. A. Anderson

Cancer Res (2022) 82 (10_Supplement): B023.

https://doi.org/10.1158/1538-7445.EVODYN22-B023

Published: 15 May 2022

View articletitled, Abstract B023: An integrated approach to understanding the evolutionary dynamics of childhood acute lymphoblastic leukemia from diagnosis to relapse

Journal Articles

Abstract PR010: Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support

Cancer Res (2022) 82 (10_Supplement): PR010.

https://doi.org/10.1158/1538-7445.EVODYN22-PR010

Published: 15 May 2022

View articletitled, Abstract PR010: Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support

Journal Articles

Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy

Maximilian A.R. Strobl, Jeffrey West, Yannick Viossat, Mehdi Damaghi, Mark Robertson-Tessi, Joel S. Brown, Robert A. Gatenby, Philip K. Maini, Alexander R.A. Anderson

Cancer Res (2021) 81 (4): 1135–1147.

https://doi.org/10.1158/0008-5472.CAN-20-0806

Published: 15 February 2021

View articletitled, Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy

Includes: Supplementary data

Journal Articles

Towards Multidrug Adaptive Therapy

Jeffrey West, Li You, Jingsong Zhang, Robert A. Gatenby, Joel S. Brown, Paul K. Newton, Alexander R.A. Anderson

Cancer Res (2020) 80 (7): 1578–1589.

https://doi.org/10.1158/0008-5472.CAN-19-2669

Published: 02 April 2020

View articletitled, Towards Multidrug Adaptive Therapy

Includes: Supplementary data

Journal Articles

Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies

Jeffrey West, Paul K. Newton

Cancer Res (2017) 77 (23): 6717–6728.

https://doi.org/10.1158/0008-5472.CAN-17-1120

Published: 30 November 2017

View articletitled, Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 3696: Evolutionary immunotherapy in NSCLC: identifying optimal dosing strategies in TIL therapy using agent-based modeling

Abstract 5571: Collagen stabilization directs immune suppression in the head and neck squamous cell carcinoma hypoxic subtype

Abstract A021: Evolutionary immunotherapy in NSCLC: An integrated approach

Abstract PR006: Evolution of evolvability

Abstract PR008: Cell state transitions drive the evolution of disease progression in B-cell acute lymphoblastic leukemia

Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics

Abstract 847: Applying the principles of convexity and concavity to guide treatment scheduling of ALK inhibitors in non-small cell lung cancer

Abstract 3164: Disulfiram re-sensitizes ER+ breast cancer cells resistant to chemotherapy through an evolutionary double-bind

Abstract 852: Predicting progression in metastatic castrate-sensitive prostate cancer by coupling PSA and testosterone dynamics to a mechanistic mathematical model

Abstract 124: Autocrine signaling extends PD-L1 expression in NSCLC following an active immune response

Abstract PR008: Immunosuppressive niche engineering at the onset of human colorectal cancer

Abstract B025: Antifragile therapy

Abstract B006: Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support

Abstract B033: Immunosuppressive niche engineering at the onset of human colorectal cancer

Abstract B023: An integrated approach to understanding the evolutionary dynamics of childhood acute lymphoblastic leukemia from diagnosis to relapse

Abstract PR010: Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support

Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy

Towards Multidrug Adaptive Therapy

Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only